Standardization of the body surface area (BSA) formula to calculate the dose of anticancer agents in Japan

Japanese Journal of Clinical Oncology

Volumn 33, Issue 6, 2003, Pages 309-313

  Kouno, Tsutomu ^a   Katsumata, Noriyuki ^a   Mukai, Hirofumi ^a   Ando, Masashi ^a   Watanabe, Toru ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Anticancer agents; Body surface area; Calculation; Dose; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CANCER; CANCER CHEMOTHERAPY; DOSE CALCULATION; HUMAN; JAPAN; MATHEMATICAL PARAMETERS; MEDLINE; STANDARDIZATION; ADULT; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; MEDICAL LITERATURE; NEOPLASM; STANDARD;

ADULT; ANTINEOPLASTIC AGENTS; BODY HEIGHT; BODY SURFACE AREA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEOPLASMS; PHARMACOPOEIAS;

EID: 0043287011     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg062     Document Type: Article

References (30)

1. Carmo-Pereira J, Costa FO, Henriques E, Henriques E, Godinho F, Cantinho-Lopes MG, et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 1987;56:471-3.
2. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
3. Samson MK, Rivkin SE, Jones SE, Costanzi JJ, LoBuglio AF, Stephens RL, et al. Dose-response and dose-survival advantage for high versus low doses cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer: A South West Oncology Group study. Cancer 1984;53: 1029-35.
4. Gurney H, Dodwell D, Thatcher N, Tattersall MH. Escalating drug delivery in cancer chemotherapy: A review of concepts and practice - Part 1. Ann Oncol 1993;4:23-34.
5. Fujimoto S, Watanabe T, Sakamoto A, Yukawa K, Morimoto K. Studies on the physical surface area of Japanese. 18. Calculation formulae in three stages over all ages. Nippon Eiseigaku Zasshi 1968;5:443-50.
6. Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth 1992;4:4-10.
7. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863-71.
8. Boyd E. Experimental error inherent in measuring growing human body. Am J Physiol 1930;13:389-432.
9. Gehan EA, George SL. Estimation of human surface area from height and weight. Cancer Chemother Rep part 1 1970;54:225-35.
10. Haycock GB, Schwarta GJ, Wistosky DH. Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adults. J Pediatr 1978;93:62-6.
11. Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987;317:1098.
12. Southwest Oncology Group: Dosing principles for patients on clinical trials. Policy memorandum No. 38. http://swog.org/Visitors/Policies.asp.
13. Reilly JJ, Workman P. Normalization of anticancer drug dosage using body weight and surface area: Is it worthwhile? Cancer Chemother Pharmacol 1993;32:411-8.
14. Gynecology Oncology Group Statistical Center: Calculating Body Surface Area. http://www.gogstats.org/
15. Personal communication with the director of Japan Clinical Oncology Group. http://www.jcog.jp/index.htm
16. Martin AD, Drinkwater DT, Clarys JP. Human body surface area: Validation of formulae based on cadaver study. Hum Biol 1984;56:475-88.
17. Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853-6.
18. Pinkel D. Cancer chemotherapy and body surface area. J Clin Oncol 1998; 16:3714-8.
19. Grochow LB, Baraldi C, Noe D. Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 1990;21:323-5.
20. Gurney H. Dose-calculation of anticancer agents: A review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-611.
21. Rarain MJ. Body-surface area as a basis for dosing of anticancer agents: science, myth or habit? J Clin Oncol 1998;16:2297-8.
22. Kunitoh H, Watanabe K. Phase I/II and pharmacologic study of long term continuous infusion etoposide combined with cisplatin in practice with advanced non-small-cell lung cancer. J Clin Oncol 1994;12:83-9.
23. Madden T, Sunderland M, Santana VM, Rodman, JH. The pharmacokinetics of high dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther 1992;51:701-7.
24. Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose-calculation. J Clin Oncol 1998;16:2299-304.
25. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001;19:3733-9.
26. Moore MJ, Enlichman C, Thiessen JJ, Bunting PS, Hardy R, Kerr I, et al. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 1994;33:472-6.
27. Launay-Iliadis MC, Bruno R, Cosson V, Vergniol JC, Oulid-Aissa D, Marty M, et al. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995;37:47-54.
28. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Calboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
29. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000; 18:2301-8.
30. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;388:499-505.